NRAS and melanoma: A novel RAF inhibitor, LXH254—which may have activity in tumors with concurrent BRAF and NRAS mutations, and in melanoma cell lines that are resistant to BRAF and MEK inhibition—was found to be less active in the KRAS mutant cell lines [31].